BEIJING (Reuters) – China National Pharmaceutical Group (Sinopharm) will need to assess results from Phase III clinical trials to decide whether its two-shot COVID-19 vaccine should be followed by a booster shot, Zhang Yuntao, vice president at China National Biotec Group (CNBG), an affiliate of Sinopharm, said on Sunday.
Antibodies triggered by two COVID-19 vaccine products from Sinopharm both have good neutralising effect on variants found in Britain and South Africa, Zhang told a news conference.
(Reporting by Roxanne Liu and Ryan Woo; Editing by Simon Cameron-Moore)
